Scios And Medtronic To Develop Heart Failure Treatment

Scios Inc. has announced its entry into a research collaboration with Medtronic, Inc. to study the effects of Scios’ investigational agent Natrecor (nesiritide) in combination with Medtronic’s heart failure devices and implantable infusion systems. “We are excited to establish this collaboration as both Scios and Medtronic have a shared commitment to the diagnosis and management Read more about Scios And Medtronic To Develop Heart Failure Treatment[…]

Biosite Diagnostics Launches Coronary Collaboration

Biosite Diagnostics Incorporated has announced the launch of a collaborative Biosite Discovery program to identify novel proteins that can advance care for patients with acute coronary syndrome, or ischemic heart disease, the most common cause of death worldwide. The collaboration leverages Biosite’s existing partnership with Large Scale Proteomics Corporation and introduces new clinical collaborators, including Read more about Biosite Diagnostics Launches Coronary Collaboration[…]

cardiovasculat collaboration

AngioSense And Repair Agree Cardiovascular Collaboration

AngioSense Inc., and Boston-based Repair Inc. are to jointly pursue clinical applications for sustained delivery of fibroblast growth factor (FGF) to stimulate the growth of new blood vessels in diseased hearts. Under the agreement, AngioSense will supply its needle-free, jet injection delivery systems and Repair will provide proprietary FGF protein and fibrinogen constructs. Financial details Read more about AngioSense And Repair Agree Cardiovascular Collaboration[…]

nortran pharmaceuticals

Nortran Signs Licensing Agreement With Astrazeneca

Under the terms of the agreement, Nortran Pharmaceuticals Inc. will grant AstraZeneca PLC an exclusive worldwide license to develop and market a novel antiarrhythmic drug candidate in exchange for upfront, milestone, and royalty payments. AstraZeneca will pay for all development and marketing costs. The agreement covers a single Nortran antiarrhythmic drug candidate, allowing Nortran the Read more about Nortran Signs Licensing Agreement With Astrazeneca[…]

genzyme corporation

Genzyme, AGTC Announce Gene Therapy Collaboration

Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield Read more about Genzyme, AGTC Announce Gene Therapy Collaboration[…]

meridian bioscience

Meridian Agrees License Deal With Corixa

Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers Read more about Meridian Agrees License Deal With Corixa[…]

diaDexus Collaborates On Cardiovascular Diagnostic

diaDexus, Inc Mayo Clinic, and Mayo Medical Laboratories, the national reference laboratory for Mayo Clinic, have entered into a collaborative agreement to explore the clinical applications for a test that detects a newly identified independent risk factor for cardiovascular disease. The test, called the PLAC Test, was developed by diaDexus as a potential new way Read more about diaDexus Collaborates On Cardiovascular Diagnostic[…]

Photoelectron Announces Strategic Partnership With Cordis

Photoelectron Corporation has signed an exclusive agreement with Cordis Corporation, a Johnson & Johnson Company, to co-develop and co- manufacture a disposable miniature x-ray source and associated technology for the delivery of intravascular radiation therapy to prevent restenosis of coronary arteries following angioplasty and stent procedures. Cordis Corporation is a leader in circulatory disease management. Read more about Photoelectron Announces Strategic Partnership With Cordis[…]

Ligand Pharmaceuticals

Ligand And Lilly Advance Novel Drugs

Ligand Pharmaceuticals Incorporated has announced that LY510929, a novel PPAR agonist, and a back-up compound have been declared clinical candidates for development as novel oral treatments for type 2 diabetes and cardiovascular disease. Ligand expects an Investigational New Drug Application (IND) to be filed with the FDA for LY510929 or the back-up compound in the Read more about Ligand And Lilly Advance Novel Drugs[…]

eli lilly

Millennium And Lilly Extend Collaboration

Millennium Pharmaceuticals, Inc. and Eli Lilly and Company have announced a one-year extension of their cardiovascular disease research collaboration. The five-year partnership, originally due to expire in October, will continue at full capacity at least through October of 2001, at which time Lilly has the option to extend for up to two additional years. Since Read more about Millennium And Lilly Extend Collaboration[…]